What is Myriad myChoice HRD?
myChoice® HRD is a test currently being developed by Myriad Genetic Laboratories, which seeks to identify patients whose tumor has Homologous Recombination Deficiency (HRD).
myChoice HRD is a tumor test and will be used to identify patients that will likely benefit from targeted therapy. Every patient’s cancer is unique, so their treatment should be as well. Myriad’s myChoice HRD helps physicians select the most effective treatment for their patients, minimizing the time and toxicity associated with ineffective therapies. myChoice HRD is currently being evaluated in clinical trials and is not yet available to order. There are many clinical trials assessing the utility of myChoice HRD in multiple tumor types. Please refer to clinicaltrials.gov for this information.
Learn more about Myriad’s myChoice® HRD